US Active Pharmaceutical Ingredient (API) Market by Type, Product and Application - Forecast and Analysis 2024-2028

Published: Feb 2024 Pages: 147 SKU: IRTNTR77525

US Active Pharmaceutical Ingredient (API) Market Forecast 2024-2028

The US active pharmaceutical ingredient market size is estimated to grow by USD 16.51 billion, at a CAGR of 7.87% between 2023 and 2028. The report includes an in-depth analysis of drivers, trends, and challenges. It examines historical data from 2018-2022, besides analyzing the current market scenario.

Apart from the increased healthcare expenditure by the urban population in the US and a rapid surge in the aged population, the market stands to gain additional traction from the increase in the number of drug master files (DMF) filing. Five types of DMFs can be granted, each requiring a different type of information. Among them, type II DMF is the most common form and covers drug substances, substance intermediates, and materials used in the preparation of a drug product. The API market in US is rapidly emerging as pharmaceutical manufacturers are increasingly relying on API manufacturers to outsource bulk actives for manufacturing generic drugs and high-end, difficult-to-manufacture patented drugs. Thus, this increasing number of type II drug master files is expected to propel the development of the market during the forecast period.

What will be the size of the US API Market during the Forecast Period?

To learn more about this report, Download Report Sample

US API Market Segmentation 

By Type Analysis

The market share by the captive API segment will be significant during the forecast period. Captive refers to the production of key pharmaceutical components within a vertically integrated company. In this context, the company that develops and manufactures the final drug product also produces its active ingredients, ensuring greater control over the entire supply chain. Furthermore, the global pharmaceutical industry is currently witnessing an increase in the expiration of patents on blockbuster drugs, which has decreased their demand significantly over the years.

The captive API segment was valued at USD 14.98 billion in 2018. Furthermore, the increasing emphasis of healthcare regulatory authorities on quality control of APIs and their production facilities is a growing concern for manufacturers, resulting in increased dependency on in-house capabilities for the manufacturing of high-quality APIs. To overcome these barriers, innovators rely on their in-house capabilities for manufacturing APIs, which is the major factor driving the growth of this segment. Thus, major market players such as Pfizer, Novartis, Sanofi, and GlaxoSmithKline are investing in in-house capabilities, which will drive the segment and thereby expand the market during the forecast period.

Get a glance at the market contribution of various segments Download PDF Sample

By Product Analysis

The generic?segment will account for the largest share of this segment.?Generic are those that are subject to patent expiry and can be manufactured and marketed by a variety of manufacturers. Additionally, generic comprise therapeutic areas, including cardiovascular, central nervous system, respiratory, anti-diabetes, and other areas. This classification enables pharmaceutical companies to tailor their strategies to the specific requirements of each therapeutic segment by taking into account the prevalence of disease, patient's needs, regulatory needs, and pricing dynamics. Thus, such features and properties will drive the demand for generic APIs and will expand the growth of the API market in the US during the forecast period.

Buy the Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc.: The company offers ingredients such as Biperiden, Cyclosporine, Dasabuvir, organometallic and gaseous HCl.

  • Amneal Pharmaceuticals Inc.,
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Bristol Myers Squibb Co.
  • Cadila Pharmaceuticals Ltd.
  • Cambrex Corp.
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Koninklijke DSM NV
  • Lupin Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.,
  • Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

US API Market Dynamics and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key trends, and challenges. 

Significant Market Trends

A paradigm shift in manufacturing is one of the primary market trends shaping development. Although the active pharmaceutical ingredient (API) market in US started catering to the early-stage intermediates, over time, outsourcing has penetrated across the value chain, including advanced intermediates to final dosage forms that are consumed by patients, particularly generic drugs. Further, the lifecycle of an API also influences the timing of outsourcing. In a post-discovery environment, multiple activities are required to be explored simultaneously. 

Additionally, with the profitability of patented drugs, reducing the time to market can result in significant financial rewards. Outsourcing enables innovators as well as generic drug manufacturers to meet aggressive development timelines while capitalizing on great efficiencies in their own supply chain. Therefore, the paradigm shift from captive API manufacturing to contract API manufacturing is anticipated to have a positive impact on the market during the forecast period.

Major Market Challenges

High investment costs and concern about huge loss is a significant challenge that affects market expansion. Establishing manufacturing facilities requires significant capital investment for infrastructure, technology, and compliance with stringent regulatory standards. This financial commitment poses a barrier for new entrants, and even existing companies are looking to expand their production capacity. The pharmaceutical industry is highly regulated, and compliance with quality standards, safety protocols, and Good Manufacturing Practices (GMP) is mandatory. Ensuring adherence to these regulations involves substantial costs for testing, validation, and continuous monitoring, contributing to the overall high investment burden.

Furthermore, the interconnected nature of the global pharmaceutical supply chain can expose companies to risks related to geopolitical events, trade disruptions, or global health crises. Companies investing extensively in production may face challenges in managing and mitigating these external risks. Thus, high investment costs and concerns of potential losses will hamper the growth of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market research and growth report forecasts market growth analysis by revenue and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Type Outlook
    • Captive API
    • Contract API
  • Product Outlook
    • Generic
    • Innovative
  • Application Outlook
    • Oncology
    • Cardiovascular diseases
    • Diabetes
    • Communicable diseases
    • Orthopedic and others

Research Analyst Overview:

The market is a dynamic arena influenced by various factors ranging from technological advancements to drug price control policies. Pharmaceutical and biopharmaceutical players are continually engaged in R&D spending to develop new molecular entities (NMEs) that cater to the evolving needs of healthcare. However, challenges such as counterfeit drugs and unfavorable drug price control policies persist, impacting profits and reimbursement strategies.

Additionally, with the emergence of precision medicine and a deeper understanding of genes and lifestyles, clinical trials now focus on achieving pharmacologically effective drug concentrations while considering the rest of the body dynamics. The market's landscape is also shaped by regulatory frameworks such as the European Falsified Medicines Directive (FMD) and initiatives led by organizations like the WHO to combat falsified or fake medicines in low- and middle-income countries.

Furthermore, API suppliers are exploring various expression systems including mammalian, microbial, yeast, and insect systems, optimizing processes for protein folding and post-translational modification to ensure safety and efficacy for human use. The industry's collaborative efforts, highlighted through conferences, webinars, and partnerships, aim to streamline the legal supply chain and uphold quality standards in an ever-evolving EU pharmaceutical industry overseen by entities like the EU Intellectual Property Office (EUIPO).

US Active Pharmaceutical Ingredient (API) Market Scope

Report Coverage

Details

Page number

147

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.87%

Market Growth 2024-2028

USD 16.51 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.79

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Koninklijke DSM NV, Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the between 2024 and 2028
  • Precise estimation of the size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across US
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Country Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 07: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 08: Parent market
    • Exhibit 09: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 10: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 11: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%)
      • Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Active pharmaceutical ingredient (API) market in US 2018 - 2022
      • Exhibit 16: Historic Market Size – Data Table on active pharmaceutical ingredient (api) market in US 2018 - 2022 ($ billion)
    • 4.2 Type Segment Analysis 2018 - 2022
      • Exhibit 17: Historic Market Size – Type Segment 2018 - 2022 ($ billion)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 18: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
    • 4.4 Application Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 21: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 22: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 23: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 24: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 25: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 26: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 27: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 28: Data Table on Type - Market share 2023-2028 (%)
    • 6.2 Comparison by Type
      • Exhibit 29: Chart on Comparison by Type
      • Exhibit 30: Data Table on Comparison by Type
    • 6.3 Captive API - Market size and forecast 2023-2028
      • Exhibit 31: Chart on Captive API - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 32: Data Table on Captive API - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 33: Chart on Captive API - Year-over-year growth 2023-2028 (%)
      • Exhibit 34: Data Table on Captive API - Year-over-year growth 2023-2028 (%)
    • 6.4 Contract API - Market size and forecast 2023-2028
      • Exhibit 35: Chart on Contract API - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Data Table on Contract API - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 37: Chart on Contract API - Year-over-year growth 2023-2028 (%)
      • Exhibit 38: Data Table on Contract API - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Type
      • Exhibit 39: Market opportunity by Type ($ billion)
      • Exhibit 40: Data Table on Market opportunity by Type ($ billion)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 41: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 42: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 43: Chart on Comparison by Product
      • Exhibit 44: Data Table on Comparison by Product
    • 7.3 Generic - Market size and forecast 2023-2028
      • Exhibit 45: Chart on Generic - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 46: Data Table on Generic - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 47: Chart on Generic - Year-over-year growth 2023-2028 (%)
      • Exhibit 48: Data Table on Generic - Year-over-year growth 2023-2028 (%)
    • 7.4 Innovative - Market size and forecast 2023-2028
      • Exhibit 49: Chart on Innovative - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 50: Data Table on Innovative - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 51: Chart on Innovative - Year-over-year growth 2023-2028 (%)
      • Exhibit 52: Data Table on Innovative - Year-over-year growth 2023-2028 (%)
    • 7.5 Market opportunity by Product
      • Exhibit 53: Market opportunity by Product ($ billion)
      • Exhibit 54: Data Table on Market opportunity by Product ($ billion)

    8 Market Segmentation by Application

    • 8.1 Market segments
      • Exhibit 55: Chart on Application - Market share 2023-2028 (%)
      • Exhibit 56: Data Table on Application - Market share 2023-2028 (%)
    • 8.2 Comparison by Application
      • Exhibit 57: Chart on Comparison by Application
      • Exhibit 58: Data Table on Comparison by Application
    • 8.3 Oncology - Market size and forecast 2023-2028
      • Exhibit 59: Chart on Oncology - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 60: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Chart on Oncology - Year-over-year growth 2023-2028 (%)
      • Exhibit 62: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
    • 8.4 Cardiovascular diseases - Market size and forecast 2023-2028
      • Exhibit 63: Chart on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 64: Data Table on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Chart on Cardiovascular diseases - Year-over-year growth 2023-2028 (%)
      • Exhibit 66: Data Table on Cardiovascular diseases - Year-over-year growth 2023-2028 (%)
    • 8.5 Diabetes - Market size and forecast 2023-2028
      • Exhibit 67: Chart on Diabetes - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 68: Data Table on Diabetes - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Chart on Diabetes - Year-over-year growth 2023-2028 (%)
      • Exhibit 70: Data Table on Diabetes - Year-over-year growth 2023-2028 (%)
    • 8.6 Communicable diseases - Market size and forecast 2023-2028
      • Exhibit 71: Chart on Communicable diseases - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on Communicable diseases - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on Communicable diseases - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on Communicable diseases - Year-over-year growth 2023-2028 (%)
    • 8.7 Orthopedic and others - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Orthopedic and others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Orthopedic and others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Orthopedic and others - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Orthopedic and others - Year-over-year growth 2023-2028 (%)
    • 8.8 Market opportunity by Application
      • Exhibit 79: Market opportunity by Application ($ billion)
      • Exhibit 80: Data Table on Market opportunity by Application ($ billion)

    9 Customer Landscape

    • 9.1 Customer landscape overview
      • Exhibit 81: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 82: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 83: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 84: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 85: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 86: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 87: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 88: AbbVie Inc. - Overview
              • Exhibit 89: AbbVie Inc. - Product / Service
              • Exhibit 90: AbbVie Inc. - Key news
              • Exhibit 91: AbbVie Inc. - Key offerings
            • 12.4 Amneal Pharmaceuticals Inc.
              • Exhibit 92: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 93: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 94: Amneal Pharmaceuticals Inc. - Key news
              • Exhibit 95: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 96: Amneal Pharmaceuticals Inc. - Segment focus
            • 12.5 Aurobindo Pharma Ltd.
              • Exhibit 97: Aurobindo Pharma Ltd. - Overview
              • Exhibit 98: Aurobindo Pharma Ltd. - Product / Service
              • Exhibit 99: Aurobindo Pharma Ltd. - Key offerings
            • 12.6 Cadila Pharmaceuticals Ltd.
              • Exhibit 100: Cadila Pharmaceuticals Ltd. - Overview
              • Exhibit 101: Cadila Pharmaceuticals Ltd. - Product / Service
              • Exhibit 102: Cadila Pharmaceuticals Ltd. - Key offerings
            • 12.7 Cipla Ltd.
              • Exhibit 103: Cipla Ltd. - Overview
              • Exhibit 104: Cipla Ltd. - Business segments
              • Exhibit 105: Cipla Ltd. - Key news
              • Exhibit 106: Cipla Ltd. - Key offerings
              • Exhibit 107: Cipla Ltd. - Segment focus
            • 12.8 Dr Reddys Laboratories Ltd.
              • Exhibit 108: Dr Reddys Laboratories Ltd. - Overview
              • Exhibit 109: Dr Reddys Laboratories Ltd. - Business segments
              • Exhibit 110: Dr Reddys Laboratories Ltd. - Key offerings
              • Exhibit 111: Dr Reddys Laboratories Ltd. - Segment focus
            • 12.9 GlaxoSmithKline Plc
              • Exhibit 112: GlaxoSmithKline Plc - Overview
              • Exhibit 113: GlaxoSmithKline Plc - Business segments
              • Exhibit 114: GlaxoSmithKline Plc - Key news
              • Exhibit 115: GlaxoSmithKline Plc - Key offerings
              • Exhibit 116: GlaxoSmithKline Plc - Segment focus
            • 12.10 Koninklijke DSM NV
              • Exhibit 117: Koninklijke DSM NV - Overview
              • Exhibit 118: Koninklijke DSM NV - Business segments
              • Exhibit 119: Koninklijke DSM NV - Key news
              • Exhibit 120: Koninklijke DSM NV - Key offerings
              • Exhibit 121: Koninklijke DSM NV - Segment focus
            • 12.11 Lupin Ltd.
              • Exhibit 122: Lupin Ltd. - Overview
              • Exhibit 123: Lupin Ltd. - Product / Service
              • Exhibit 124: Lupin Ltd. - Key news
              • Exhibit 125: Lupin Ltd. - Key offerings
            • 12.12 Novartis AG
              • Exhibit 126: Novartis AG - Overview
              • Exhibit 127: Novartis AG - Business segments
              • Exhibit 128: Novartis AG - Key offerings
              • Exhibit 129: Novartis AG - Segment focus
            • 12.13 Pfizer Inc.
              • Exhibit 130: Pfizer Inc. - Overview
              • Exhibit 131: Pfizer Inc. - Product / Service
              • Exhibit 132: Pfizer Inc. - Key news
              • Exhibit 133: Pfizer Inc. - Key offerings
            • 12.14 Sanofi SA
              • Exhibit 134: Sanofi SA - Overview
              • Exhibit 135: Sanofi SA - Business segments
              • Exhibit 136: Sanofi SA - Key news
              • Exhibit 137: Sanofi SA - Key offerings
              • Exhibit 138: Sanofi SA - Segment focus
            • 12.15 Sun Pharmaceutical Industries Ltd.
              • Exhibit 139: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 140: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 141: Sun Pharmaceutical Industries Ltd. - Key news
              • Exhibit 142: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 143: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 144: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 145: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 146: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 147: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 148: Viatris Inc. - Overview
              • Exhibit 149: Viatris Inc. - Business segments
              • Exhibit 150: Viatris Inc. - Key news
              • Exhibit 151: Viatris Inc. - Key offerings
              • Exhibit 152: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 153: Inclusions checklist
                • Exhibit 154: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 155: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 156: Research methodology
                • Exhibit 157: Validation techniques employed for market sizing
                • Exhibit 158: Information sources
              • 13.5 List of abbreviations
                • Exhibit 159: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              active pharmaceutical ingredient (api) market in us market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis